Evidence map›Paper›PMID 33660372›Full record

ArticleHead & neck2021

Human epidermal growth factor receptor 2 expression in head and neck squamous cell carcinoma: Variation within and across primary tumor sites, and implications for antigen-specific immunotherapy.

Emilie A K Warren, Joshua Anil, Patricia D Castro, Jan Kemnade, Masataka Suzuki, Meenakshi Hegde, John Hicks, Wendong Yu, Vlad Sandulache, Andrew G Sikora

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Head & neck, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Assessment of EGFR and HER2 expression in penile cancer as potential therapeutic targets.Virchows Archiv : an international journal of pathology · 2026
    Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Emilie A K WarrenDepartment of Otolaryngology - Head and Neck Surgery, Baylor College of Medicine, Houston, Texas, USA.
Joshua AnilDepartment of Otolaryngology - Head and Neck Surgery, Baylor College of Medicine, Houston, Texas, USA.
Patricia D CastroDepartment of Pathology and Immunology, Baylor College of Medicine, Houston, Texas, USA.
Jan KemnadeDepartment of Medicine, Section of Hematology and Oncology, Baylor College of Medicine, Houston, Texas, USA.
Masataka SuzukiCenter for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA.
Meenakshi HegdeCenter for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA.
John HicksDepartment of Pathology and Immunology, Baylor College of Medicine, Houston, Texas, USA.
Wendong YuDepartment of Pathology and Immunology, Baylor College of Medicine, Houston, Texas, USA.
Vlad SandulacheDepartment of Otolaryngology - Head and Neck Surgery, Baylor College of Medicine, Houston, Texas, USA.ORCID 0000-0002-9205-385X
Andrew G SikoraDepartment of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Baylor College of Medicine · USMichael E. DeBakey VA Medical Center · USThe University of Texas MD Anderson Cancer Center · US

Funding

Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Michael M Ittmann · 2007 to 2026
$73.9M
BCM Oncology Scholars Training ProgramT32CA174647 · NCI · BAYLOR COLLEGE OF MEDICINE · PI LIN, WEEI-CHIN · 2014 to 2018
$1.2M
Improving Treatment Algorithms for Veterans with Oropharyngeal CancerIK2CX001953 · VA · MICHAEL E DEBAKEY VA MEDICAL CENTER · PI SANDULACHE, VLAD C · 2020 to 2022
–
CSRD VA IK2 CX001953NCI NIH HHS P30 CA125123NCI NIH HHS T32 CA174647
6 · The paper itself

Abstract

backgroundThe purpose of this study is to describe human epidermal growth factor 2 (HER2) overexpression in head and neck squamous cell carcinoma (HNSCC) and re-evaluate its potential as a target for HER2-directed immunotherapies.

methodsA retrospective cohort of patients with HNSCC receiving curative treatment was identified, and HER2 expression evaluated in archival tissue by immunohistochemistry and correlated with clinicopathological characteristics. HER2 expression data were also determined for HNSCC patients in The Cancer Genome Atlas.

resultsNineteen percent of HNSCC and 39% of oropharyngeal HNSCC (OPSCC) were HER2 positive. HER2 expression positively correlated with nodal metastasis (p = 0.035). Patients with HER2-positive tumors had decreased overall survival (p = 0.012), including within the human papilloma virus-positive OPSCC subgroup (p = 0.007).

conclusionsA substantial fraction of HNSCC overexpresses HER2 protein, suggesting it may be a suitable target for antigen-directed immunotherapy. HER2 expression and its correlation with survival vary across HNSCC subsites, making it unsuitable as a prognostic marker.

Indexed as

Carcinoma, Squamous CellHead and Neck NeoplasmsErb-b2 Receptor Tyrosine KinasesHumansImmunotherapyRetrospective StudiesSquamous Cell Carcinoma of Head and NeckERBB2 protein, humanErb-b2 Receptor Tyrosine Kinaseshead and neck squamous cell carcinomahuman epidermal growth factor receptor 2 human papilloma virus immunotherapy oropharynx

Identifiers

PMID33660372
PMCPMC10320663
OpenAlexW3135024119

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.